Moreover, a recent study demonstrated that treatment with EGFR-TKIs may change the tumor microenvironment by increasing PD-L1 expression (Figure 3) and TMB, while modifying CD8+/FOXP3 TILs and CD73 expression. This evidence concerns the gene EGFR and neoplasm.